Member Info for gjbrandon

@13thMonkey It is interesting you mentioned Theranos. As an engineer, I was fascinated by the concept behind the objective of what Elizabeth Holmes sought to achieve in her Theranos project. If you watched the HBO documentary "Out for Blood in Silicon Valley" you see where there was so many moving parts inside the diagnostic equipment. Moving chemicals and blood samples, assays and contents of pipettes poses a high risk of cross contamination.

A single drop onto another area could undermine all future testing without the inside being cleaned out after each test. Most technology pioneers who set out to create something new, fail, or at best, are held back because they are creating as they go along.

But success is best built on the failures, or failings and mistakes of those gone before. Windows, and Apple user display on their computers. Nokia, Apple, Samsung and Huawei on smart phones.

Integumen's Rinocloud AI system for detecting e.coli in 4 seconds was built on top of collections of sampled water, brought to be laboratory and processed by lab technicians growing bacteria over 24 to 72 hours to confirm that the water source is contaminated.

Modern Water's Microtox equipment use bio luminescent reagents, which lose their brightness if contaminated with a range of virus, toxins and other bacteria to trigger an alarm, confirming the water source is contaminated.

Adding those two elements together is logical. Both work and have done over a number of years.

Looking for a specific target in contaminated water (like SARS-CoV-2) is better if you have a proven virus capturing agent (Affimers from Avacta and Aptamers from the Aptamer Group)

Pulling all three proven technologies together builds on the success, out of failed experiments over years, to get it right.

Theranos sought the Holy Grail, without a map or milestones. Whether it is liquid from water, blood or milk (mastitis), once you have the pieces that already work, then the outcomes becomes more certain.

One final lessons on Theranos. Don't use moving parts that carry liquids, as the risk of drips and spills and cross-contamination lead to one failing that should be overcome with any future solution. We know that lesson is costly, and eliminated it before it became an issue.

@coolcatcol In shares, no salary.

I also made the point on the same BB that before anyone goes into tin-hat overdrive, the guy is not in the company. He was Founder of Rinocloud in 2016 and left that company before it was acquired by Integumen in May 2019. He was on a soft-lock-in, so it was properly managed by the Broker.

@Tatty99 The core competence in Cellulac is bacteria, Enzymes and fluid dynamics in high volume waterl landfill leachate, algal extraction of oils without solvents.

Hope that explains the connection with water (long before we got involved in Modern Water) we were experts in processing water in factories).
Systems in Cellulac have been designed to operate at up to 9300 litres PER MINUTE in ethanol, breweries.

@Paulcon If you know I can't answer it, why ask :) Regardless, those timescales for us are unrealistic.

@havelot these are valid questions and part of the testing protocols that will be ongoing for many weeks, even after the results of tests currently underway.

@travel_light There are outstanding aspects to the findings of a test review published last week in the Lancet
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30630-7/fulltext

These should be open for discussion:
a) Immunity passports based on antibody tests or tests for infection face substantial technical, legal, and ethical challenges;
b) current testing methods alone can't reduce R0 below 1

An alternative is necessary and that is what we are working on

Would you believe it, but as part of my fund manager days, I used to be invested in a nightclub in The Netherlands in the 90's. Yeah, I thought it was a good idea at the time. So, I am aware of the issues around the hospitality sector, which has been badly hit. The solution is an instant real-time test that allows entry. It is not good enough just to make an announcement to the media that someone in a laboratory has had a Eureka moment. You have to provide a full end-to-end solution.

That requires collaboration partners, supply chain management, revenue share to keep the cost of production low, a monthly recurring rental scheme (as someone rightly pointed out) willing partners in the hospitality sector.

As an hospitality group mentioned in this thread used to have 154,000 patrons every Saturday night at their clubs. That amounted to an 11 million a year clientele. Diddly-squat since April. I won't do the math, but if the minimum entry requirement was a real-time test that cost the price of a pint and the outcome was knowing that every person in the club took the test and passed it. How valuable to the community, the club owners and the providers of tests is that?

@RorkesDrift. There is a difference to how long droplets (greater than 5 micron) and aerosols (smaller than 5 micron) remain in the air, particularly in a confined space. Real simple terms Aerosols may reach the lung while droplets tend to linger in the upper respiratory tract (where they take the swaps from). The smaller the particle is, the longer it is likely to stay in the air. Published data suggest that droplets (larger size) have a higher transmission rate than aerosols.

Coughing, sneezing or singing are more likely to transmit, than normal breathing. So how hard would it be to capture and tell everyone that someone in the room is infectious?

Let's make it vivid. If 50 people were in a large function room and one person on one side of the room were smoking, the other side would perhaps be subject to secondary smoke only if there was no real air circulation and to be honest the amount would be nominal. Same applies to a swimming pool. 50 people in a pool, one kid has a pee. Same scenario, yuckier vivid image :)

The point I am making is that the amount of volume of air in the room is critical to whether you can check for the virus in droplets of one or two people in a large area and likely you would miss it.

Better option is to have everyone test before you go into the room. That is the current problem in need of a real-time solution. That is what we have been working on and will reveal soon

@Glebe there are many companies involved in studies. Many take time to bring to the point of starting for many reasons. The more data in the market the better. Our tests are a work in progress

I have been working with many of the Integumen team since 2003. 17 years of perfecting this business model

@DAFAD I cringe when I rewatch this video from 2005, but if you want to know what we do best and how quickly we can provide a global solution it is in the first 60 seconds

https://twitter.com/Jey73132087/status/1297275022801874944?s=20

We fund our own IP, take no funding from innovation grants and enter no royalty free program. If our system works and clients want it, we own the IP. Also innovation funding is a minefield of process and procedure that gets in the way of real innovation.

For instance even working from failure of a process requires documentation to report on the failure and request permission to alter course of innovation. Fk that. Test, fail, try something else. Same day, not 3 weeks of paperwork first.

Love funding when it comes, but not a huge fan.

@Lunsam it doesn't go unnoticed inside Integumen either. The more real research the less we have to correct rumours.

Thank you

@Chesh That is a very good explanation of what we are doing at Integumen. Our objective is not to sell a product or service, but a solution comprised of integrated elements that increase average revenue per client. Everyone wins, we get consistent sales revenues from multiple clients, not reliant on a single large buyer. It also means that future growth opportunities can be based in securitising future revenues based on recurring revenue models.

If you don't object I will tweet on that link
https://www.inc.com/anne-gherini/the-rise-of-rundle-a-new-trend-for-subscription-based-services.html

@Paulcon62 we are a little ahead of your thought process. News and updates on this will be out in due course

@PL75 you are in the ball park, buy not quite there yet. What we are working on is unique and assuming it does work (no reason to suspect it wouldn't) as we are working with tried and tested equipment, it is likely to change the way we look at the virus. Proactively fighting back as a society, rather than reacting to the damage it does to individuals.

I have no need or desire to sell anything relating to Integumen or ModernWater

I haven't sold a share and have absolutely no interest in doing so

29,404,762 warrants exercised as shares
60% of those are Helium Rising Star Fund (holding long term)
14,130,218 is the number of shares traded today
40% of warrants exercised is 11,761,905 (excluding Helium 60%)

2.36m more shares were traded in one day, above the number of free shares released by warrants